Arog Pharmaceuticals, a late-stage biotech developing oral small molecule kinase inhibitors for cancer, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
The Dallas, TX-based company was founded in 2010 and plans to list on the Nasdaq under the symbol AROG. Arog Pharmaceuticals filed confidentially on September 24, 2018. Citi, RBC Capital Markets and Nomura Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
